Skip to main content
Quest Diagnostics

Evaluation of a Whole Genome Sequencing Approach in a Clinical Context

ASHG 2025

American Society of Human Genetics

Boston, MA, Oct 14-18, 2025

Poster presentation: Evaluation of a Whole Genome Sequencing Approach in a Clinical Context

Pg. 347

Authors: Fuligni F, Pollock S, Sass C,  Bogumil D, Soifer I, Iremadze N,  Lowman G, Cherel S, Elzinga C, Angeloni T, Veeraraghavan R

Medical Specialty: Genetics

Related content

Conference Presentation
Analytical Performance Evaluation of Whole Genome Sequencing as First-line Genetic Testing for Intellectual Development Disorders and Congenital Malformations
The Utility of Exome Sequencing for Neurodevelopmental Disorders at a Large Reference Laboratory
Publication
Learning the Cellular Origins Across Cancers Using Single-Cell Chromatin Landscapes

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.